Changes to standard
Standards Australia Committee ME-002-04 has agreed to adopt ISO 11623:2002 "Transportable gas cylinders " Periodic inspection and testing of composite gas cylinders' with national modifications.
This Standard will supersede AS 2337.3:1998 "Gas cylinder test stations " Inspection and testing of fibre reinforced plastic (FRP) gas cylinders'.
The committee's decision to replace AS 2337.3 with the adoption of an ISO Standard is based on the following:
- Currently, there is no manufacturing of composite cylinders to an Australian Standard, and so no requirement for inspection or test parameters that are uniquely Australian;
- ISO 11623 gas has evolved to become a technically superior Standard concerning the examination and testing requirements of composite cylinders, and one which is not in conflict with AS 2337.3.
This Standard specifies requirements for periodic inspection and testing of hoop wrapped and fully wrapped composite transportable gas cylinders intended for compressed, liquefied or dissolved gases under water pressure capacity of 0.5 " 450 litres.
The main change to this Standard is the replacement of some of the normative references with relevant AS and ISO Standards. This is because some requirements of the ISO specification are in conflict with the requirements in the applicable Australian Standards or regulations.
Another change is the removal of Tables 1 to 4 in the current ISO Standard, which is replaced by a new Table on Periodic inspection and test intervals for all composite coming up cylinders. This is due to the requirements of the ISO specification being in conflict with applicable Australian Standards or regulations.
The revised Standard is due to be published in September 2007.
To stay up to date and view a full list of drafts for comment visit Standards Australia
QIMR Berghofer signs strategic partnership with Nakanoshima Qross
QIMR Berghofer and Japanese biomedical innovation hub Nakanoshima Qross have signed a strategic...
Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director
Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...
